Non-Hodgkin’s Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017

Date: November 1, 2010
Pages: 83
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N49D61A4E47EN
Leaflet:

Download PDF Leaflet

Non-Hodgkin’s Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017
Non-Hodgkin’s Lymphoma (NHL) – Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist has released a new report, “Non-Hodgkin’s Lymphoma (NHL) – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global Non-Hodgkin’s Lymphoma (NHL) market to be worth $6.5 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 7.74% annually over the next eight years to reach $11.9 billion by 2017. This growth can be primarily attributed to increased competition among the existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The NHL market growth will be further supported by the increased uptake of chemotherapy regimens, monoclonal antibodies and biologics. In 2009, Genentech Inc. (Roche), with its key drug Rituxan, was the leading player in the global NHL market. In 2009, Rituxan played a key role accounting to more than 80% share in the global NHL market. Pharmaceuticals and biopharmaceutical companies are under the way in reorganizing their NHL pipeline with combination therapies. There are six approved drugs in 2008, and two new drugs were approved by FDA in the first quarter of 2009. NHL pipeline is strong with 264 drugs under different stages of clinical development. Drugs that are studied with Rituxan either belong to the new mechanism of action or to the existing/old mechanism of action. Combination therapies in clinical studies projected to be more efficacious and safer than monotherapies alone. In future, the NHL market is driven by combination therapies, monoclonal antibodies, biologics, and vaccines. GlobalData analyzed that the global NHL market is moderately served with current product options with significant scope available to new entrants that would capture value from underserved segments.

GlobalData analyzes that the global NHL market would double its revenues by 2017. In 2009, Genentech, Inc. accounted to be the NHL market leader with a share of more than 80%, which was contributed by its key drug Rituxan. Forthcoming monotherapies and combination therapies would much more satisfy NHL patients with safer drug profiles. The competitive landscape is populated by eight major products, of which two drugs were launched in the first half of 2009. All these drugs were moderately successful in increasing the survival rate of patients with NHL. However, companies like GlaxoSmithKline plc. (GSK), Biogen Idec, Genzyme Corporation, Genitope Corporation, Hana Biosciences, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc. and Novartis AG, Pfizer Inc. / Wyeth having some of the most technologically advanced products in their pipeline, are expected to attract most of the investors attention. The global NHL market is expected to see intense competition in the future.

Scope

The report analyzes market opportunities and challenges for the global NHL market. Its scope includes
  • Annualized global NHL market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
  • Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include CD targetors, anti-CD20 monoclonal antibodies, antineoplastic agents, histone deacetylase inhibitors, B-cell lymphoma 2 inhibitors, CD22 antigens, anti-angiogenesis inhibitors, DNA synthesis inhibitors, syk kinase inhibitors and proteasome inhibitors.
  • Analysis of the current and future market competition in the global NHL market. Key market players covered are Genentech Inc., GSK, Biogen Idec, Genzyme Corporation, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc. / Wyeth, and Genitope Corporation.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NHL

    Reasons to buy

    The report will enhance your decision making capability. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global NHL market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NHL market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global NHL market landscape? – Identify, understand and capitalize.
  • 1 TABLE OF CONTENTS

    1.1 List of Tables
    1.2 List of Figures

    2 NON-HODGKIN’S LYMPHOMA MARKET : INTRODUCTION

    2.1 GlobalData Pipeline Report Guidance

    3 NON-HODGKIN’S LYMPHOMA MARKET: MARKET CHARACTERIZATION

    3.1 Overview
    3.2 Non-Hodgkin’s Lymphoma Market Size
    3.3 Non-Hodgkin’s Lymphoma Market Forecast and CAGR
    3.4 Drivers and Barriers for the Non-Hodgkin’s Lymphoma Market
      3.4.1 Drivers for the Non-Hodgkin’s Lymphoma Market
      3.4.2 Barrier for the Non-Hodgkin’s Lymphoma Market
    3.5 Opportunity and Unmet Need
    3.6 Key Take Away

    4 NON-HODGKIN’S LYMPHOMA MARKET: COMPETITIVE ASSESSMENT

    4.1 Overview
    4.2 Strategic Competitor Assessment
    4.3 Product Profile for the Major Marketed Products in the Non-Hodgkin’s Lymphoma Market
      4.3.1 Rituxan (MabThera)
      4.3.2 Velcade
      4.3.3 Bexxar
      4.3.4 Zevalin
      4.3.5 Treanda
      4.3.6 Campath (MabCampath or Campath-1H)
    4.4 Recently Approved NHL Drugs for Non-Hodgkin’s Lymphoma
      4.4.1 Folotyn
      4.4.2 Mozobil
    4.5 Key Take Away

    5 NON-HODGKIN’S LYMPHOMA MARKET: PIPELINE ASSESSMENT

    5.1 Overview
    5.2 Strategic Pipeline Assessment
      5.2.1 Technology Trends Analytical Framework
    5.3 Non-Hodgkin’s Lymphoma Therapeutics – Promising Drugs under Clinical Development
    5.4 Molecule Profile for Promising Drugs under Clinical Development
      5.4.1 BiovaxID
      5.4.2 Afinitor
      5.4.3 Reviroc
      5.4.4 Ontak
      5.4.5 LY317615
      5.4.6 Pixantrone
    5.5 Non-Hodgkin’s Lymphoma Therapeutic Market – Clinical Pipeline by Mechanism of Action
    5.6 Non-Hodgkin’s Lymphoma Pipeline – Pipeline by Phases of Development
      5.6.1 Non-Hodgkin’s Lymphoma Therapeutics Pipeline – Phase III Clinical Studies
      5.6.2 Non-Hodgkin’s Lymphoma Therapeutics Pipeline – Phase II Clinical Studies
      5.6.3 Non-Hodgkin’s Lymphoma Therapeutics Pipeline – Phase I Clinical Studies
      5.6.4 Non-Hodgkin’s Lymphoma Therapeutics Pipeline – Preclinical Studies
    5.7 Discontinued/Suspended Drugs for Non-Hodgkin’s Lymphoma
    5.8 Key Take Away

    6 GLOBAL NON-HODGKIN’S LYMPHOMA MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

    6.1 Strategic Competitor Assessment

    7 GLOBAL NON-HODGKIN’S LYMPHOMA MARKET: FUTURE PLAYERS IN THE NON-HODGKIN’S LYMPHOMA MARKET

    7.1 Introduction
    7.2 Genentech, Inc. (Roche)
      7.2.1 Company Overview
      7.2.2 Business Description
      7.2.3 Company Pipeline
    7.3 GlaxoSmithKline plc. (GSK)
      7.3.1 Company Overview
      7.3.2 Business Description
      7.3.3 Company Pipeline
    7.4 Immunomedics, Inc.
      7.4.1 Company Overview
      7.4.2 Business Description
      7.4.3 Company Pipeline
    7.5 Seattle Genetics, Inc.
      7.5.1 Company Overview
      7.5.2 Business Description
      7.5.3 Company Pipeline
    7.6 Eli Lilly and Company
      7.6.1 Company Overview
      7.6.2 Business Description
      7.6.3 Company Pipeline
    7.7 Pfizer Inc. (Wyeth)
      7.7.1 Company Overview
      7.7.2 Business Description
      7.7.3 Company Pipeline
    7.8 Novartis
      7.8.1 Company Overview
      7.8.2 Business Description
      7.8.3 Company Pipeline
    7.9 Biogen Idec
      7.9.1 Company Overview
      7.9.2 Business Description
      7.9.3 Company Pipeline
    7.10 Genzyme Corporation
      7.10.1 Company Overview
      7.10.2 Business Description
      7.10.3 Company Pipeline

    8 NON-HODGKIN’S LYMPHOMA MARKET: APPENDIX

    8.1 Definitions
    8.2 Scope of Pipeline Research
    8.3 Abbreviations
    8.4 Research Methodology
      8.4.1 Coverage
      8.4.2 Secondary Research
      8.4.3 Forecasting
      8.4.4 Primary Research
      8.4.5 Expert Panel validation
    8.5 Contact Us
    8.6 Disclaimer
    8.7 Sourcess

    LIST OF TABLES

    Table 1: Non-Hodgkin’s Lymphoma, Global, Revenue ($bn), 2001–2009
    Table 2: Non-Hodgkin’s Lymphoma Market, Global, Revenues ($bn), 2009–2017
    Table 3: Major Marketed Products Comparison in Non-Hodgkin’s Lymphoma Market, 2010
    Table 4: Non-Hodgkin’s Lymphoma Therapeutics – Most Promising Drugs in Clinical Development, 2010
    Table 5: NHL Therapeutics Pipeline – Phase III Clinical Studies, 2010
    Table 6: NHL Therapeutics Pipeline – Phase II Clinical Studies, 2010
    Table 7: NHL Therapeutics Pipeline – Phase I Clinical Studies, 2010
    Table 8: NHL Therapeutics Pipeline – Preclinical Studies, 2010
    Table 9: List of Discontinued/Suspended Drugs for Non-Hodgkin’s Lymphoma, 2010
    Table 10: F. Hoffmann-La Roche Ltd. - Oncology Pipeline Products, 2010
    Table 11: F. Hoffmann-La Roche Ltd. - Non-Hodgkin’s Lymphoma Pipeline Products, 2010
    Table 12: Genentech Inc. – Oncology Product Pipeline, 2010
    Table 13: Genentech Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 14: GlaxoSmithKline plc. – Oncology Product Pipeline, 2010
    Table 15: GlaxoSmithKline plc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 16: Immunomedics, Inc. – Oncology Product Pipeline, 2010
    Table 17: Immunomedics, Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 18: Seattle Genetics, Inc. – Oncology Product Pipeline, 2010
    Table 19: Seattle Genetics, Inc. – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 20: Eli Lilly and Company – Oncology Product Pipeline, 2010
    Table 21: Eli Lilly and Company – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 22: Pfizer Inc. (Wyeth) – Oncology Product Pipeline, 2010
    Table 23: Pfizer Inc. (Wyeth) – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 24: Novartis – Oncology Product Pipeline, 2010
    Table 25: Novartis – Non-Hodgkin’s Lymphoma Product Pipeline, 2010
    Table 26: Biogen Idec – Oncology Product pipeline, 2010
    Table 27: Biogen Idec – Non-Hodgkin’s Lymphoma Product pipeline, 2010
    Table 28: Genzyme Corporation – Oncology Product pipeline, 2010
    Table 29: Genzyme Corporation – Non-Hodgkin’s Lymphoma Product pipeline, 2010 75

    LIST OF FIGURES

    Figure 1: Non-Hodgkin’s Lymphoma, Global, Revenue ($bn), 2001–2009
    Figure 2: Non-Hodgkin’s Lymphoma, Global, Market Forecast ($bn), 2009–2017
    Figure 3: Opportunity and Unmet Need in the Non-Hodgkin’s Lymphoma Market, 2010
    Figure 4: Strategic Competitor Assessment, 2010
    Figure 5: Technology Trends Analytic Framework – NHL Market, 2010
    Figure 6: Technology Trends Analytic Framework of the NHL Pipeline – Description, 2010
    Figure 7: NHL Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
    Figure 8: NHL Pipeline by Phase of Clinical Development, 2010
    Figure 9: Implications for Future Market Competition in Non-Hodgkin’s Lymphoma, 2010
    Figure 10: NHL Therapeutics Market – Clinical Pipeline by Company, 2010
    Figure 11: GlobalData Market Forecasting Model 81

    COMPANIES MENTIONED

    Genentech, Inc. (Roche)
    GlaxoSmithKline plc. (GSK)
    Immunomedics, Inc.
    Seattle Genetics, Inc.
    Eli Lilly and Company
    Pfizer Inc. (Wyeth)
    Novartis
    Biogen Idec
    Genzyme Corporation

    Ask Your Question

    Non-Hodgkin’s Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry: